Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma | Zendy

Shu-De Feng | Zendy; Ziming Mao | Zendy; Chunying Liu | Zendy; YuSong Nie | Zendy; Bin Sun | Zendy; Minggao Guo | Zendy; Changqing Su | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma

Author(s) -

Shu-De Feng,

Ziming Mao,

Chunying Liu,

YuSong Nie,

Bin Sun,

Minggao Guo,

Changqing Su

Publication year - 2017

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s149632

Subject(s) - adenocarcinoma , cancer research , medicine , microrna , pancreatic ductal adenocarcinoma , pancreatic cancer , oncology , biology , gene , cancer , genetics

Pancreatic adenocarcinoma (PAC) is one of the most fatal cancers due to its high degree of malignancy, increasing incidence, high mortality, and unsatisfactory treatment efficacy. Evidence has suggested that numerous microRNAs (miRNAs), including miR-126 and miR-34a, have potent tumor-suppressing effects on PAC, implicating a possible application of miRNA in tumor therapy. However, the therapeutic effect of a single miRNA on pancreatic cancer is limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research